Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant

After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.

Emergent BioSolutions
emergent vaccine drug substance quarantined, production suspended • Source: Alamy

In a move that underscores the high cost of poor quality in a pandemic, Emergent BioSolutions, Inc. is suspending production of COVID-19 vaccine drug substance in the midst of the race to reach herd immunity against the coronavirus and its emerging variants.

Emergent agreed to a request from the US Food and Drug Administration to suspend manufacturing operations and quarantine the drug...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet